Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Francois Goelo who wrote (12540)	7/19/1999 9:26:00 AM
From: RCJIII	Read Replies (1) \| Respond to of 52051

Big news out on UPCA, could be today's biggest mover- (COMTEX) B: New Technologies & Concepts, Inc. Receives Patient Docume B: New Technologies & Concepts, Inc. Receives Patient Documentation From Govt. Of Spain Following Announcement Of Major Breakthrough In Field Of HIV Research LAS VEGAS, Jul 19, 1999 (BW HealthWire via COMTEX) -- New Technologies & Concepts, Inc. (NTC), a Research and Development Company, announced today that as a follow-up to its announcement on June 16, 1999 ofits major breakthrough in the fight against the human immunodeficiency virus (HIV), it has received documentation from the Government of Spain verifying the authenticity of the patients who have been treated and sent letters regarding their treatment. Their regular monthly checkups have shown no recurrence of the virus to date. In fact, ONE HUNDRED PERCENT (100%) of the patients tested showed COMPLETE REVERSAL of the HIV virus with VIRTUALLY NO SIDE EFFECTS! The founder of the company, Alfred Flores, an honor graduate of the University of Madrid and the University of Colorado, has done extensive research into the area of immunology at his own laboratory located just outside of Lisbon, in Portugal. It was there that he developed the Plasma Plus formula, which was used to treat these patients. The letters received further verify that the tests conducted on patients in Madrid, which showed complete reversal from the immune system of the HIV infection, still show no reintroduction of the virus after a period of more than eighteen months. The letters give the patient's name and address, their patient number, identification number, their original CD-4 counts at the commencement of the treatment, and their current CD-4 counts after more than 18 months. The patients were originally diagnosed with AIDS in 1995 at the Hospital of Madrid and Mr. Flores was then given permission by the courts to treat them with Plasma Plus which is done, in most cases, over a 3-month period. This documentation verifies that all of the patients have been tested monthly at the General Hospital in Madrid over the past 18 months. Their blood profiles show that prior to being administered the Plasma Plus treatment, some of the patients had CD-4 counts under 400, usually associated with AIDS, and some even as low as 200. They are all currently in the normal 800 - 1,200 CD-4 count range and aside from taking vitamins and following a low calorie diet, they have not taken any medication of any kind for the virus since the original Plasma Plustreatments. Results from the findings of the Plasma Plus treatment are nothing short of "Phenomenal," according to the doctors in Madrid who oversaw the treatments. The majority stockholder in NTC is Uniprime Capital Acceptance, Inc. (OTC BB: UPCA) of Las Vegas, Nevada, a diversified holding company involved in the acquisition of retail automotive dealerships throughout the United States, along with planned expansion into the areas of non-prime financing, industry consulting and insurance-related services. NTC and Uniprime are currently working on additional sites around the world to demonstrate the results of Plasma Plus before embarking on a worldwide marketing campaign. The documentation regarding five (5) of the patients will be posted on the Uniprime web-site which is located at: www.uniprimeinc.com . In addition to the testimonials of the patients, three (3) of the doctors who participated in the study will be forwarding their own WRITTEN TESTIMONIALS as to the results of the tests and this information is expected to be in the hands of Mr. Flores and top Uniprime personnel by next week. For further information, please contact Mr. Alfred Flores through the corporate offices of Uniprime at 1-888-892-2002 Or 1-702-798-5420. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products or delays in testing and evaluation of products or in information supplied by others and other risks detailed from time to time in company documents furnished to investors. Copyright (C) 1999 Business Wire. All rights reserved. -0- CONTACT: Uniprime